Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
34
BDRX Quote, Financials, Valuation and Earnings
Last price:
$0.85
Seasonality move
:
-11.97%
Day range:
$0.80 - $0.85
52-week range:
$0.78 - $25.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.87x
P/B ratio:
0.41x
Volume:
799.3K
Avg. volume:
2.9M
1-year change:
-96.61%
Market cap:
$4.2M
Revenue:
$474.1K
EPS (TTM):
-$74.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$11.1M | -$0.14 | -91.39% | -8.33% | $1.45 |
|
AUTL
Autolus Therapeutics PLC
|
$12.9M | -$0.23 | -80.39% | -10.73% | $9.86 |
|
BCYC
Bicycle Therapeutics PLC
|
$9.4M | -$0.93 | 0.73% | -20.58% | $26.27 |
|
DBVT
DBV Technologies SA
|
$747.8K | -$0.18 | -- | -84.24% | $16.06 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
$0.84 | $17.94 | $4.2M | -- | $0.00 | 0% | 0.87x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.27 | $1.45 | $71.6M | -- | $0.00 | 0% | 0.39x |
|
AUTL
Autolus Therapeutics PLC
|
$2.44 | $9.86 | $649.4M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$7.78 | $26.27 | $538.8M | -- | $0.00 | 0% | 19.61x |
|
DBVT
DBV Technologies SA
|
$9.79 | $16.06 | $267.8M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.05 | $104.00 | $304.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.010 | -- | 1.20x |
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.289 | 50.03% | 1.57x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.256 | -- | 8.74x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.061 | -- | 14.57x |
|
DBVT
DBV Technologies SA
|
-- | -2.552 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -1.015 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$70M | -27.79% | -28.27% | -619.32% | -$87M |
|
DBVT
DBV Technologies SA
|
-- | -$26.6M | -- | -- | -- | -$19.7M |
|
NCNA
NuCana PLC
|
-- | -$3.5M | -- | -- | -- | -$4M |
Biodexa Pharmaceuticals PLC vs. Competitors
-
Which has Higher Returns BDRX or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -653.18%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M -
What do Analysts Say About BDRX or ADAP?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 2041.28%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.45 which suggests that it could grow by 437.5%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 ADAPAdaptimmune Therapeutics PLC2 4 0 -
Is BDRX or ADAP More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.167, which suggesting that the stock is 16.654% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.923%.
-
Which is a Better Dividend Stock BDRX or ADAP?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or ADAP?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 0.87x versus 0.39x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC0.87x -- -- -- ADAPAdaptimmune Therapeutics PLC0.39x -- $7.3M -$47.6M
-
Which has Higher Returns BDRX or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -781.13%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About BDRX or AUTL?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 2041.28%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 303.92%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is BDRX or AUTL More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.167, which suggesting that the stock is 16.654% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.299%.
-
Which is a Better Dividend Stock BDRX or AUTL?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or AUTL?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $9M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 0.87x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC0.87x -- -- -- AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns BDRX or BCYC?
Bicycle Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -608.94%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Bicycle Therapeutics PLC's return on equity of -28.27%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M -
What do Analysts Say About BDRX or BCYC?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 2041.28%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $26.27 which suggests that it could grow by 237.7%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is BDRX or BCYC More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.167, which suggesting that the stock is 16.654% more volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.784%.
-
Which is a Better Dividend Stock BDRX or BCYC?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or BCYC?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $10M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Bicycle Therapeutics PLC's net income of -$60.8M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 0.87x versus 19.61x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC0.87x -- -- -- BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M
-
Which has Higher Returns BDRX or DBVT?
DBV Technologies SA has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M DBVTDBV Technologies SA-- -$1.30 -- -
What do Analysts Say About BDRX or DBVT?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 2041.28%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 64.81%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than DBV Technologies SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 DBVTDBV Technologies SA1 0 0 -
Is BDRX or DBVT More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.167, which suggesting that the stock is 16.654% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.
-
Which is a Better Dividend Stock BDRX or DBVT?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or DBVT?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than DBV Technologies SA's net income of -$27.1M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 0.87x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC0.87x -- -- -- DBVTDBV Technologies SA-- -- -- -$27.1M
-
Which has Higher Returns BDRX or NCNA?
NuCana PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M NCNANuCana PLC-- -$0.63 -- -
What do Analysts Say About BDRX or NCNA?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 2041.28%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 207071.32%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 NCNANuCana PLC0 1 0 -
Is BDRX or NCNA More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.167, which suggesting that the stock is 16.654% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.
-
Which is a Better Dividend Stock BDRX or NCNA?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or NCNA?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than NuCana PLC's net income of -$3.1M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 0.87x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC0.87x -- -- -- NCNANuCana PLC-- -- -- -$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
